ClinicalTrials.gg
RecruitingNCT07431983Updated May 12, 2026

Prospective Evaluation of the Carbon Footprint and Clinical Utility of IBUS Compared to Colonoscopy and Enterography in UC and CD

An observational study in Ulcerative Colitis (UC) and Crohns Disease, sponsored by Asian Institute of Gastroenterology, India. Recruiting at 2 sites in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Asian Institute of Gastroenterology, India · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Colitis, Ulcerative with a site in India — 10 open to participants now, 20 under way, 8 of them phase 3. Colitis, Ulcerative · India.

Started
2026
with 3 others
Observational
2 of 58
1 open now
Primary completion
2026-12
later than 8 of 19 live
Registered
55th of 58
by date
Lead sponsor
7 of 58
Asian Institute of Gastroenterology, India

Among the 58 studies in Colitis, Ulcerative with a site in India, this one is one of 4 that started in 2026, is one of 2 observational ones, reaches primary completion later than 8 of the 19 other live ones, and was the 55th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

10 of the 58 studies in Colitis, Ulcerative with a site in India are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Colitis, Ulcerative with a site in India, or all of them as a file.
02

Study summary

Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD.

Read the detailed description

Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD. Its low energy footprint and portability make it a potential frontline tool for sustainable IBD follow-up. This study aims to quantify and compare the environmental impact and diagnostic value of IBUS versus conventional imaging strategies in real-world clinical care.

03

Conditions studied

  • Ulcerative Colitis (UC)
  • Crohns Disease
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Duration: 12 months

Sample Size:

100 UC patients (Colonoscopy + IBUS), 100 CD patients (CT/MRI enterography + IBUS), Total: 200 Patients

Eligibility criteria

All consecutive patients undergoing endoscopy procedures with consent for procedures, during the study period will be included

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ulcerative colitis

    carbon footprint and clinical usefulness of Intestinal Bowel Ultrasound (IBUS) with standard imaging colonoscopy in patients with Ulcerative Colitis Colonoscopy+ IBUS

  • Crohns disease

    carbon footprint and clinical usefulness of Intestinal Bowel Ultrasound (IBUS) with standard imaging CT/MRI enterography in patients with Crohn's Disease CT/MRI enterography+ IBUS

06

What researchers measure

Primary outcomes

  1. The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed

    The waste generated will be stratified according to the methods of disposal as Direct landfill, Incineration, and landfill or Recyclable waste. The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed. The unit of emissions will remain same kgCO2e and the total emissions will then be calculated.

    Time frame: 12 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Expert Panel on Pediatric Imaging; Moore MM, Gee MS, Iyer RS, Chan SS, Ayers TD, Bardo DME, Chandra T, Cooper ML, Dotson JL, Gadepalli SK, Gill AE, Levin TL, Nadel HR, Schooler GR, Shet NS, Squires JH, Trout AT, Wall JJ, Rigsby CK. ACR Appropriateness Criteria(R) Crohn Disease-Child. J Am Coll Radiol. 2022 May;19(5S):S19-S36. doi: 10.1016/j.jacr.2022.02.020. PubMed 35550801 ↗
  • Namburar S, von Renteln D, Damianos J, Bradish L, Barrett J, Aguilera-Fish A, Cushman-Roisin B, Pohl H. Estimating the environmental impact of disposable endoscopic equipment and endoscopes. Gut. 2022 Jul;71(7):1326-1331. doi: 10.1136/gutjnl-2021-324729. Epub 2021 Dec 1. PubMed 34853058 ↗
  • Lenzen M, Malik A, Li M, Fry J, Weisz H, Pichler PP, Chaves LSM, Capon A, Pencheon D. The environmental footprint of health care: a global assessment. Lancet Planet Health. 2020 Jul;4(7):e271-e279. doi: 10.1016/S2542-5196(20)30121-2. PubMed 32681898 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's planned 9 months is below that.

Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Feb 25, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07431983
Responsible party
Mohan Ramchandani (Consultant Gastroenterology, Asian Institute of Gastroenterology, India) — Principal investigator
First posted
Feb 25, 2026
Start date
Mar 1, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 12, 2026

Study contacts

Dr.Hardik Rughwani
Contact
dr.hardikr@aighospitals.com
9426928600

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion